Expression of human immunodeficiency virus type 1 tat from a replication-deficient herpes simplex type 1 vector induces antigen-specific T cell responses (Q45413779)

From Wikidata

Jump to navigation Jump to search

scientific article published on 12 July 2006

Language	Label	Description	Also known as
English	Expression of human immunodeficiency virus type 1 tat from a replication-deficient herpes simplex type 1 vector induces antigen-specific T cell responses	scientific article published on 12 July 2006

Statements

scholarly article

1 reference

Europe PubMed Central

14 December 2017

Expression of human immunodeficiency virus type 1 tat from a replication-deficient herpes simplex type 1 vector induces antigen-specific T cell responses (English)

1 reference

Europe PubMed Central

14 December 2017

vector-borne disease

0 references

8

1 reference

Europe PubMed Central

14 December 2017

Roberto Manservigi

object named as

Roberto Manservigi

6

0 references

Antonella Caputo

object named as

Antonella Caputo

5

0 references

object named as

Barbara Ensoli

7

0 references

author name string

Aleksandra Bozac

1

1 reference

Europe PubMed Central

14 December 2017

Elena Berto

2

1 reference

Europe PubMed Central

14 December 2017

Federica Vasquez

3

1 reference

Europe PubMed Central

14 December 2017

Paola Grandi

4

1 reference

Europe PubMed Central

14 December 2017

language of work or name

0 references

publication date

12 July 2006

1 reference

Europe PubMed Central

14 December 2017

number of pages

11

1 reference

based on heuristic

inferred from page(s)

1 reference

Europe PubMed Central

14 December 2017

24

1 reference

Europe PubMed Central

14 December 2017

49-50

1 reference

Europe PubMed Central

14 December 2017

7148-7158

1 reference

Europe PubMed Central

14 December 2017

Future vaccines: recent advances and future prospects

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

The past, present and future of HIV-vaccine development: a critical view.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

Substantial differences in specificity of HIV-specific cytotoxic T cells in acute and chronic HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

Clinical trials of HIV vaccines.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

Memory T cells and vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

Rev activity determines sensitivity of HIV-1-infected primary T cells to CTL killing.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

Cytotoxic T-lymphocyte (CTL) responses directed against regulatory and accessory proteins in HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

Correlation between breadth of memory HIV-specific cytotoxic T cells, viral load and disease progression in HIV infection.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

Catastrophes after crossing species barriers

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

Vaccination with Rev and Tat against AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

HIV-1 Tat-based vaccines: from basic science to clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

A novel chimeric Rev, Tat, and Nef (Retanef) antigen as a component of an SIV/HIV vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

Gene combination raises broad human immunodeficiency virus-specific cytotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

The HIV-1 regulatory proteins Tat and Rev are frequently targeted by cytotoxic T lymphocytes derived from HIV-1-infected individuals

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

Human immunodeficiency virus type 1 Rev- and Tat-specific cytotoxic T lymphocyte frequencies inversely correlate with rapid progression to AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

Vaccination with DNA containing tat coding sequences and unmethylated CpG motifs protects cynomolgus monkeys upon infection with simian/human immunodeficiency virus (SHIV89.6P).

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

Vaccine development against HIV-1: current perspectives and future directions.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

A new generation of HIV vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

Virus-based vectors for human vaccine applications

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

Live Recombinant Vectors for AIDS Vaccine Development

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

Development of a DNA-MVA/HIVA vaccine for Kenya

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

Induction of primary virus-cross-reactive human immunodeficiency virus type 1-neutralizing antibodies in small animals by using an alphavirus-derived in vivo expression system

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

Alphavirus replicon particles as candidate HIV vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

Insertion of HIV-1 Genes into Ad4ΔE3 Vector Abrogates Increased Pathogenesis in Cotton Rats Due to E3 Deletion

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

Development of an adenovirus-shedding assay for the detection of adenoviral vector-based vaccine and gene therapy products in clinical specimens

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

A retroviral DNA vaccine vector

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

Efficient transduction of dendritic cells and induction of a T-cell response by third-generation lentivectors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

FIV vaccine development and its importance to veterinary and human medicine: a review FIV vaccine 2002 update and review

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

Vaccine protection against simian immunodeficiency virus by recombinant strains of herpes simplex virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

Expression of the human immunodeficiency virus gag gene products by a replication-incompetent herpes simplex virus vector

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

Expression of human immunodeficiency virus type 1 gp120 from herpes simplex virus type 1-derived amplicons results in potent, specific, and durable cellular and humoral immune responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

Robust recall and long-term memory T-cell responses induced by prime-boost regimens with heterologous live viral vectors expressing human immunodeficiency virus type 1 Gag and Env proteins

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

Evaluation in Rhesus Macaques of Tat and Rev-Targeted Immunization as a Preventive Vaccine against Mucosal Challenge with SHIV-BX08

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

Immunogenicity of herpes simplex virus type 1 mutants containing deletions in one or more alpha-genes: ICP4, ICP27, ICP22, and ICP0.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

Modulation of mucosal and systemic immunity by enteric administration of nonreplicating herpes simplex virus expressing cytokines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

Replication-defective herpes simplex virus vectors for gene transfer in vivo

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

Development of herpes simplex virus replication-defective multigene vectors for combination gene therapy applications

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

Herpes simplex virus vectors elicit durable immune responses in the presence of preexisting host immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

Synthesis of the complete trans-activation gene product of human T-lymphotropic virus type III in Escherichia coli: demonstration of immunogenicity in vivo and expression in vitro

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

Three novel genes of human T-lymphotropic virus type III: immune reactivity of their products with sera from acquired immune deficiency syndrome patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

Deletion of multiple immediate-early genes from herpes simplex virus reduces cytotoxicity and permits long-term gene expression in neurons

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

Rapid method for construction of recombinant HSV gene transfer vectors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

A sensitive promoter assay based on the transcriptional activator Tat of the HIV-1 virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

A quantitative assay for trans-activation by HIV-1 Tat, using liposome-mediated DNA uptake and a parallel ELISA system

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

HIV-1 Tat protein exits from cells via a leaderless secretory pathway and binds to extracellular matrix-associated heparan sulfate proteoglycans through its basic region

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

Identification of a peptide capable of inducing an HIV-1 Tat-specific CTL response

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

Novel biocompatible anionic polymeric microspheres for the delivery of the HIV-1 Tat protein for vaccine application

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

Micellar-type complexes of tailor-made synthetic block copolymers containing the HIV-1 tat DNA for vaccine application

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

Immunization with low doses of HIV-1 tat DNA delivered by novel cationic block copolymers induces CTL responses against Tat.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

Vaccines based on the native HIV Tat protein and on the combination of Tat and the structural HIV protein variant ΔV2 Env

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

Preparation of clinical-grade recombinant canarypox-human immunodeficiency virus vaccine-loaded human dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

Tumor regression induced by intratumor therapy with a disabled infectious single cycle (DISC) herpes simplex virus (HSV) vector, DISC/HSV/murine granulocyte-macrophage colony-stimulating factor, correlates with antigen-specific adaptive immunity.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

Effect of prior exposure to herpes simplex virus 1 on viral vector-mediated tumor therapy in immunocompetent mice.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

Pre-existing herpes simplex virus 1 (HSV-1) immunity decreases, but does not abolish, gene transfer to experimental brain tumors by a HSV-1 vector

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

Complement depletion facilitates the infection of multiple brain tumors by an intravascular, replication-conditional herpes simplex virus mutant

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

Deletion of the virion host shutoff protein (vhs) from herpes simplex virus (HSV) relieves the viral block to dendritic cell activation: potential of vhs- HSV vectors for dendritic cell-mediated immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

Nucleic acid vaccination with HIV regulatory genes: a combination of HIV-1 genes in separate plasmids induces strong immune responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

Codon optimization of the tat antigen of human immunodeficiency virus type 1 generates strong immune responses in mice following genetic immunization

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

DNA vaccination in mice using HIV-1 nef, rev and tat genes in self-replicating pBN-vector

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

Protection from bacterial infection by a single vaccination with replication-deficient mutant herpes simplex virus type 1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

Recent advances in the development of HIV-1 Tat-based vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 protein

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

DNA prime/protein boost immunization against HIV clade C: safety and immunogenicity in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

A call for replicating vector prime-protein boost strategies in HIV vaccine design

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

Protection against mucosal simian immunodeficiency virus SIV(mac251) challenge by using replicating adenovirus-SIV multigene vaccine priming and subunit boosting

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

Enhanced immunogenicity of gp120 protein when combined with recombinant DNA priming to generate antibodies that neutralize the JR-FL primary isolate of human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

Replication-defective viruses as vaccines and vaccine vectors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

Identifiers

10.1016/J.VACCINE.2006.06.061

1 reference

Europe PubMed Central

14 December 2017

1 reference

Europe PubMed Central

14 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45413779&oldid=2076854829"